| Line 45: | Line 45: | ||
<a class="dropdown-item" href="https://2017.igem.org/Team:NYU_Abu_Dhabi/Parts">Parts</a> | <a class="dropdown-item" href="https://2017.igem.org/Team:NYU_Abu_Dhabi/Parts">Parts</a> | ||
<a class="dropdown-item" href="https://2017.igem.org/Team:NYU_Abu_Dhabi/Demonstrate">Demo</a> | <a class="dropdown-item" href="https://2017.igem.org/Team:NYU_Abu_Dhabi/Demonstrate">Demo</a> | ||
| − | |||
<a class="dropdown-item" href="https://2017.igem.org/Team:NYU_Abu_Dhabi/Design">Design</a> | <a class="dropdown-item" href="https://2017.igem.org/Team:NYU_Abu_Dhabi/Design">Design</a> | ||
</div> | </div> | ||
| Line 71: | Line 70: | ||
<div class="dropdown-menu" aria-labelledby="navbarDropdownMenuLink"> | <div class="dropdown-menu" aria-labelledby="navbarDropdownMenuLink"> | ||
<a class="dropdown-item" href="https://2017.igem.org/Team:NYU_Abu_Dhabi/HP">Human Practices</a> | <a class="dropdown-item" href="https://2017.igem.org/Team:NYU_Abu_Dhabi/HP">Human Practices</a> | ||
| − | <a class="dropdown-item" href="https://2017.igem.org/Team:NYU_Abu_Dhabi/HP/Silver"> | + | <a class="dropdown-item" href="https://2017.igem.org/Team:NYU_Abu_Dhabi/HP/Silver">Human Practices</a> |
| − | <a class="dropdown-item" href="https://2017.igem.org/Team:NYU_Abu_Dhabi/HP/Gold_Integrated">Integrated Practices</a> | + | <a class="dropdown-item" href="https://2017.igem.org/Team:NYU_Abu_Dhabi/HP/Gold_Integrated">Integrated Human Practices</a> |
<a class="dropdown-item" href="https://2017.igem.org/Team:NYU_Abu_Dhabi/Engagement">Engagement and Education</a> | <a class="dropdown-item" href="https://2017.igem.org/Team:NYU_Abu_Dhabi/Engagement">Engagement and Education</a> | ||
</div> | </div> | ||
| Line 206: | Line 205: | ||
<div class = "col-lg-4 footer-section"> | <div class = "col-lg-4 footer-section"> | ||
<img class = "footer-logo" src="https://static.igem.org/mediawiki/2017/7/71/IDT.png" /> | <img class = "footer-logo" src="https://static.igem.org/mediawiki/2017/7/71/IDT.png" /> | ||
| + | <img class = "footer-logo2" src="https://static.igem.org/mediawiki/2017/2/2d/T--UrbanTundra_Edmonton--igemlogo.jpg" /> | ||
<img class = "footer-logo" src="https://static.igem.org/mediawiki/2017/c/c8/NYU_Abu_Dhabi.png" /> | <img class = "footer-logo" src="https://static.igem.org/mediawiki/2017/c/c8/NYU_Abu_Dhabi.png" /> | ||
</div> | </div> | ||
We participated in Dusseldorf Cologne postcard campaign in which we designed a postcard combining the Abu Dhabi skyline and the LAMP reaction that is integral to our project. We wrote a small description of our project on the back, and the postcards were distributed to all participating teams from around the world. Therefore, STEC-illnesses are still a major problem in countries that revolve around street food.
Groningen iGEM team participated in our virtual conference, and both the initial call and the follow-up calls were successful. Their project was to build a phage detection for Lactococcus Lactis, but were having trouble with the BioBrick 3A assembly and building their device. We suggested that they try using the pJET vector for transformation and implementing a valving system in their device. For the GFP amplification issues they were facing, team Vilnius-Lithuania suggested that they express transcription factors that can bind to multiple sequences at a time to amplify their signal.
Vilnius-Lithuania iGEM team participated in our virtual conference, and both the initial call and the follow-up calls were successful. Their project was to have a synthetic replicant to effectively keep different plasmids in one cell with the ability to control the copy number of each plasmid group separately. We looked into the issue of calculating copy number, while they helped us look at our microfluidic chambers.
We participated in the microfluidics survey for Boston University Hardware. We participated in the cholera survey for INSA-UPS Toulouse. We participated in the cattle survey for University Nebraska-Lincoln. We participated in the air pollution survey for Pasteur Paris. We participated in the GM medicine survey for Cardiff University. We participated in the insulin accessibility survey for University of Sydney. We participated in the psicose survey for Evry Paris-Saclay. We participated in the diagnosis device survey for Munich. We participate in the perspectives on treatments for illness survey for Columbia NY.
